US Bancorp DE Sells 101 Shares of Masimo Co. (NASDAQ:MASI)

US Bancorp DE decreased its position in Masimo Co. (NASDAQ:MASI) by 2.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,370 shares of the medical equipment provider’s stock after selling 101 shares during the period. US Bancorp DE’s holdings in Masimo were worth $583,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Roubaix Capital LLC boosted its stake in Masimo by 37.0% during the third quarter. Roubaix Capital LLC now owns 34,041 shares of the medical equipment provider’s stock worth $4,539,000 after acquiring an additional 9,202 shares in the last quarter. SteelPeak Wealth LLC bought a new stake in Masimo in the 3rd quarter valued at about $570,000. State of Alaska Department of Revenue increased its position in Masimo by 7.2% in the 3rd quarter. State of Alaska Department of Revenue now owns 5,139 shares of the medical equipment provider’s stock valued at $685,000 after buying an additional 345 shares in the last quarter. Allspring Global Investments Holdings LLC raised its stake in Masimo by 5,340.9% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,394 shares of the medical equipment provider’s stock worth $319,000 after buying an additional 2,350 shares during the period. Finally, Cardinal Capital Management grew its stake in Masimo by 19.9% in the third quarter. Cardinal Capital Management now owns 18,517 shares of the medical equipment provider’s stock valued at $2,469,000 after acquiring an additional 3,077 shares during the period. Institutional investors own 85.96% of the company’s stock.

Masimo Trading Up 0.7 %

NASDAQ:MASI opened at $162.41 on Monday. Masimo Co. has a 52 week low of $81.82 and a 52 week high of $173.90. The firm has a 50-day moving average price of $133.52 and a two-hundred day moving average price of $125.93. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.15 and a current ratio of 2.01. The firm has a market cap of $8.70 billion, a price-to-earnings ratio of 112.01 and a beta of 0.97.

Masimo (NASDAQ:MASI) last issued its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.14. The business had revenue of $504.60 million for the quarter, compared to analyst estimates of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. Masimo’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period last year, the company posted $0.63 earnings per share. On average, equities analysts expect that Masimo Co. will post 4.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Wells Fargo & Company upped their target price on Masimo from $160.00 to $171.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. Raymond James upgraded shares of Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 price objective on the stock in a report on Wednesday, November 6th. BTIG Research lifted their price objective on shares of Masimo from $166.00 to $170.00 and gave the company a “buy” rating in a report on Monday, October 14th. Piper Sandler boosted their target price on shares of Masimo from $165.00 to $180.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research note on Wednesday, November 6th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $163.67.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.